Lucid Diagnostics Inc. has announced a new share issuance under a Sales Agreement with Maxim Group LLC as the sales agent. The company plans to offer and sell shares of its common stock, with a maximum value of $25 million, through an "at the market offering." The proceeds from this offering are intended for working capital and general corporate purposes. The shares are being offered based on an effective shelf registration statement under the Securities Act, with a related prospectus supplement already filed with the SEC.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.